Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesLong-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: An observational study
Epilepsia, 07/01/09
Cho YJ et al. – Low-dose and slow-dose escalation of topiramate (TPM) in add-on therapy for pts with refractory partial epilepsy is effective and well tolerated in long-term, individualized clinical practice.
Methods- Retrospective, single-center, long-term observational study of long-term efficacy and tolerability of TPM as add-on therapy in pts with refractory partial epilepsy
- Subjects: Pts fulfilling Berg medical intractability criteria with newly prescribed TPM as add-on therapy between January 2000-June 2002
- Usual starting dosage of TPM: 50 mg/day
- Optimal-dose adjustments based on individual clinical responses
- Analysis of efficacy and tolerability every year during 5-yr follow-up in intention-to-treat (ITT) population
- Of 125 study pts, 107 (85.6%) followed for 5 yrs
- Retention rate: 87.2% at 1 yr; 64% at 5 yrs
- At end of 5 yrs, 69.0% median seizure frequency reduction rate; 43.2% responder rate in ITT population
- Cumulative seizure-free rate (SFR): 30.4%
- Terminal 1-yr SFR: 12.8% in ITT population (20.0% in completers) at 5-yr follow-up
- Adverse events (AEs) in 39.2% of pts, including significant AEs leading to antiepileptic drug (AED) withdrawal in 14.4%
- Most common AEs: anorexia (16.0%), weight loss (10.4%), gastrointestinal symptoms (8.8%)
- Concomitant AEDs reduced in 25.0% of completers
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09
Escitalopram and Venlafaxine for the Prophylaxis of Migraine Headache Without Mood Disorders
Clinical Neuropharmacology, 10/02/09
Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09
Sponsor
Article Search
Sponsor